|
|
Blood, 15 February 2005, Vol. 105, No. 4, pp. 1383-1395.
Prepublished online as a Blood First Edition Paper on October 7, 2004; DOI 10.1182/blood-2004-07-2909.
 Previous Article | Table of Contents | Next Article 
REVIEWS IN TRANSLATIONAL HEMATOLOGY
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Klaus Podar, and
Kenneth C. Anderson
From the Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Abstract
Besides its role as an essential regulator of physiologic and pathologic angiogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopoiesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. M. L. Coluccia, T. Cirulli, P. Neri, D. Mangieri, M. C. Colanardi, A. Gnoni, N. Di Renzo, F. Dammacco, P. Tassone, D. Ribatti, et al.
Validation of PDGFR{beta} and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
Blood,
August 15, 2008;
112(4):
1346 - 1356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Huston, X. Leleu, X. Jia, A.-S. Moreau, H. T. Ngo, J. Runnels, J. Anderson, Y. Alsayed, A. Roccaro, S. Vallet, et al.
Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment
Clin. Cancer Res.,
February 1, 2008;
14(3):
865 - 874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Scavelli, G. Di Pietro, T. Cirulli, M. Coluccia, A. Boccarelli, T. Giannini, G. Mangialardi, R. Bertieri, A. M. L. Coluccia, D. Ribatti, et al.
Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma
Mol. Cancer Ther.,
December 1, 2007;
6(12):
3256 - 3262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Molica, M. Montillo, D. Ribatti, R. Mirabelli, A. Tedeschi, F. Ricci, S. Veronese, A. Vacca, and E. Morra
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia
Haematologica,
October 1, 2007;
92(10):
1367 - 1374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Samaras, S. Bauer, F. Stenner-Liewen, R. Steiner, M. Zweifel, C. Renner, and A. Knuth
Treatment of POEMS syndrome with bevacizumab
Haematologica,
October 1, 2007;
92(10):
1438 - 1439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Youssoufian, D. J. Hicklin, and E. K. Rowinsky
Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5544s - 5548s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Pillozzi, M. F. Brizzi, P. A. Bernabei, B. Bartolozzi, R. Caporale, V. Basile, V. Boddi, L. Pegoraro, A. Becchetti, and A. Arcangeli
VEGFR-1 (FLT-1), {beta}1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome
Blood,
August 15, 2007;
110(4):
1238 - 1250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Riccioni, D. Diverio, G. Mariani, S. Buffolino, V. Riti, E. Saulle, E. Petrucci, M. Cedrone, F. Lo-Coco, R. Foa, et al.
Expression of Tie-2 and Other Receptors for Endothelial Growth Factors in Acute Myeloid Leukemias Is Associated with Monocytic Features of Leukemic Blasts
Stem Cells,
August 1, 2007;
25(8):
1862 - 1871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tzankov, S. Heiss, S. Ebner, W. Sterlacci, G. Schaefer, F. Augustin, M. Fiegl, and S. Dirnhofer
Angiogenesis in nodal B cell lymphomas: a high throughput study
J. Clin. Pathol.,
May 1, 2007;
60(5):
476 - 482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Gratzinger, S. Zhao, R. J. Marinelli, A. V. Kapp, R. J. Tibshirani, A. S. Hammer, S. Hamilton-Dutoit, and Y. Natkunam
Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes
Am. J. Pathol.,
April 1, 2007;
170(4):
1362 - 1369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Cervi, Y. Shaked, M. Haeri, T. Usenko, C. R. Lee, J. J. Haigh, A. Nagy, R. S. Kerbel, E. Yefenof, and Y. Ben-David
Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia
Blood,
March 1, 2007;
109(5):
2139 - 2146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar, M. S. Raab, J. Zhang, D. McMillin, I. Breitkreutz, Y.-T. Tai, B. K. Lin, N. Munshi, T. Hideshima, D. Chauhan, et al.
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)
Blood,
February 15, 2007;
109(4):
1669 - 1677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
298 - 327.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar, G. Tonon, M. Sattler, Y.-T. Tai, S. LeGouill, H. Yasui, K. Ishitsuka, S. Kumar, R. Kumar, L. N. Pandite, et al.
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
PNAS,
December 19, 2006;
103(51):
19478 - 19483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Wu, Z. Zhong, J. Huber, R. Bassi, B. Finnerty, E. Corcoran, H. Li, E. Navarro, P. Balderes, X. Jimenez, et al.
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Clin. Cancer Res.,
November 1, 2006;
12(21):
6573 - 6584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Vacca, C. Scavelli, G. Serini, G. Di Pietro, T. Cirulli, F. Merchionne, D. Ribatti, F. Bussolino, D. Guidolin, G. Piaggio, et al.
Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma
Blood,
September 1, 2006;
108(5):
1661 - 1667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al.
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Blood,
May 15, 2006;
107(10):
4053 - 4062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fragoso, T. Pereira, Y. Wu, Z. Zhu, J. Cabecadas, and S. Dias
VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease
Blood,
February 15, 2006;
107(4):
1608 - 1616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Roccaro, T. Hideshima, N. Raje, S. Kumar, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Ribatti, B. Nico, A. Vacca, et al.
Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells
Cancer Res.,
January 1, 2006;
66(1):
184 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Badros, N. Porter, and A. Zimrin
Bevacizumab therapy for POEMS syndrome
Blood,
August 1, 2005;
106(3):
1135 - 1135.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Vacca
New aspects of myeloma management
Blood,
July 15, 2005;
106(2):
395 - 395.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K. C. Anderson
Proteasome inhibitor therapy in multiple myeloma
Mol. Cancer Ther.,
April 1, 2005;
4(4):
686 - 692.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
